HemoSonics wins in product launch and business
expansion categories as more hospitals adopt its
Quantra® Hemostasis System for acute bleeding
management
DURHAM,
N.C., Oct. 5, 2023 /PRNewswire/ -- HemoSonics, a
medical device company delivering individualized diagnostic
solutions for acute care bleeding and the management of
coagulation, announced today that the company has won in both the
Product Launch and Business Expansion categories in the 2023
Medical Device Network Excellence Awards. HemoSonics' Quantra
Hemostasis System provides comprehensive whole-blood coagulation
analysis at the point of care in less than 15 minutes. Clinicians
don't need to wait on test results during a serious
life-threatening bleeding event, and, as a result, patients receive
optimized interventions as quickly as possible and only when
needed.
The Medical Device Network Excellence Awards is an independent
recognition program powered by the business intelligence of
GlobalData. Researchers and journalists, along with artificial
Intelligence, analyze over one billion datasets during the year,
then recognize, endorse, and rank top-tier companies and their
achievements in 200+ countries. During the evaluation period,
HemoSonics secured 510(k) clearance for the
QStat® Cartridge from the U.S. Food and Drug
Administration (FDA), allowing its Quantra Hemostasis System to be
used in laboratory and point-of-care settings for trauma and liver
transplantation procedures. HemoSonics also received an innovative
technology contract award from Vizient, opening the door for the
System to be adopted by hospitals and academic medical centers
across the United States.
"These awards validate the hard work and dedication of the
HemoSonics team and our healthcare partners to advance technology
that improves patient care and outcomes," said Bob Roda, President and CEO of HemoSonics. "At
the same time, we are just getting started. We will continue to
innovate and bring to the healthcare marketplace, new technology
solutions to support our clinical partners and hospitals transform
patient care, preserve blood, and reduce healthcare resource
utilization."
The Quantra Hemostasis System consists of the Quantra Hemostasis
Analyzer with QPlus® and QStat Cartridges. Quantra is
FDA-cleared for use in point-of-care settings, such as operating
rooms, intensive care units, and in hospital laboratories, and
requires minimal resources to maintain, operate, and to interpret.
HemoSonics' medical device technology is proven to help patients
and hospitals: a 2023 Journal of Cardiothoracic Surgery study
showed the Quantra Hemostasis System reduced blood component
transfusions between 10% and >90%. This led to a 41% decrease in
the cost of blood products - a major expense for hospitals. It is
also recognized that with improved outcomes supported by reduced
exposure to risky blood component therapy, additional cost and
efficiency benefits are realized.
About HemoSonics
HemoSonics, LLC is a medical device
technology company focused on acute bleeding management, resulting
in better patient care and lower overall medical costs. The Quantra
Hemostasis Analyzer, HemoSonics' flagship product, is designed to
improve upon existing strategies for bleeding management, and
support better patient outcomes and reduce healthcare costs. The
Quantra System's easy and fast interpretation enables simple, more
efficient, point-of-care bleeding management. Based in Durham, NC, HemoSonics is part of the Stago
Group, a leading in vitro diagnostics company dedicated to
thrombosis and hemostasis. Visit HemoSonics.com to learn more.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hemosonics-wins-medical-device-network-excellence-award-in-two-categories-301947999.html
SOURCE HEMOSONICS LLC
